A FACTOR IX (FIX) GENE TRANSFER, MULTI CENTER EVALUATION OF THE LONG TERM SAFETY AND EFFICACY STUDY OF PF 06838435 AND A DOSE ESCALATION SUBSTUDY IN INDIVIDUALS WITH HEMOPHILIA B
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Fidanacogene-elaparvovec (Primary)
- Indications Haemophilia B
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Dec 2023 Results reporting descriptive data on impact on HRQoL for participants in the fidanacogene elaparvovec phase 1/2a study (NCT02484092) and its LTU study (NCT03307980) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 08 Jun 2023 Primary and secondary endpoint measures amended.
- 08 Jun 2023 Planned End Date changed from 22 Apr 2029 to 29 May 2029.